Gene-Edited immune cells offer new hope for kids with relapsed leukemia
NCT ID NCT05942599
First seen Jan 18, 2026 · Last updated May 23, 2026 · Updated 22 times
Summary
This early-phase study tests a new treatment called BE CAR-33 in 10 children aged 6 months to 16 years whose acute myeloid leukemia has returned. The therapy uses donor immune cells that are genetically edited to better target and kill leukemia cells after chemotherapy. The main goal is to check safety and see if it can clear the leukemia enough for a successful bone marrow transplant, which aims to keep the cancer from coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED ACUTE MYELOID LEUKAEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Great Ormond Street Hospital for Children
London, WC1N3JH, United Kingdom
Conditions
Explore the condition pages connected to this study.